Skip to main content

Year: 2023

Collective Audience Appoints Technology Visionary, Investor, and Executive Leader, Peter Bordes, as Chief Executive Officer

Peter BordesCollective Audience Appoints Technology Visionary, Investor, and Executive Leader, Peter Bordes, as Chief Executive OfficerNEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) — Collective Audience, Inc. (Nasdaq: CAUD), a leading innovator of audience based performance advertising and media solutions, has appointed Peter Bordes as chief executive officer, succeeding Brent Suen who will continue to serve on the board of directors.A lifelong entrepreneur, operator and venture investor, Bordes brings to the company more than 30 years of executive and board experience leading private and public companies across the AdTech, media, AI, fintech and technology sectors. His career and investing have focused on innovation and disruptive technologies that drive digital transformation. “I have followed Peter’s career since the early...

Continue reading

Alto Ingredients, Inc. Publishes Sustainability Summary

PEKIN, Ill., Dec. 11, 2023 (GLOBE NEWSWIRE) — Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols and essential ingredients, has published its inaugural Sustainability Summary outlining the company’s performance in key areas, such as environmental, health and safety, along with the strategy and vision for advancements in sustainability, responsible sourcing, and risk management. “As a renewables company, we are dedicated to implementing sustainable best practices that are good for our business, our stakeholders and our planet,” said Bryon McGregor, President and CEO of Alto Ingredients. “From integrating innovative practices at our facilities that ensure optimal efficiency, contributing to a lower carbon footprint with our ethanol fuel, and to giving back to the community through...

Continue reading

KH Group’s has made follow-on investment in Indoor

KH Group PlcPress Release 11 December 2023 at 3:30 pm EET KH Group’s has made follow-on investment in Indoor KH Group together with other shareholders of Indoor Group Holding Oy (“Indoor”) have made combined EUR 2.8 million follow-on investments in Indoor. These follow-on investments were made by subordinated loan. Loan proceeds are used to repay interest-bearing debts. The follow-on investments strengthen Indoor’s balance sheet accordingly. KH Group Plc’s share of the subordinated loan in Indoor is EUR 2.1 million. This arrangement has been finalised today and will not affect the ownership structure in Indoor Group Holding Oy. KH GROUP PLC FURTHER INFORMATION: CEO Lauri Veijalainen, puh. +358 46 876 1648 DISTRIBUTION: Major mediawww.khgroup.com Sievi Capital is now a conglomerate with a new name KH Group. Our four business areas are...

Continue reading

Allison Abraham Retires as Co-Chair and Member of the Beyond, Inc. Board of Directors

Marcus Lemonis will serve as the Chairman of the Board MIDVALE, Utah, Dec. 11, 2023 (GLOBE NEWSWIRE) — Beyond, Inc., (NYSE: BYON) (“Beyond” or the “Company”), the parent company of online furniture and home furnishings retailer Bed Bath & Beyond, formerly known as Overstock, today announced that, on December 10, 2023, Allison H. Abraham notified the Board of Directors of Beyond (“the Board”) of her decision to retire. As part of that transition, Ms. Abraham resigned as a Director of the Company, effective immediately. Marcus Lemonis will transition to the role of Chairman of the Company’s Board of Directors. Ms. Abraham said, “I thank the Board, management, and rest of the Beyond family for their support over the years. It has been an honor to work for the Company and represent our shareholders for more than two decades....

Continue reading

FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

– PDUFA goal date is May 14, 2024 COPENHAGEN, Denmark, Dec. 11, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review the Company’s resubmitted New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adult patients with hypoparathyroidism. The agency considered the resubmission a complete, class 2 response and set a Prescription Drug User Fee Act (PDUFA) goal date of May 14, 2024. In the United States, TransCon PTH (palopegteriparatide) is an investigational prodrug of parathyroid hormone (PTH [1-34]) for adult patients with hypoparathyroidism. “We are pleased that the FDA can continue its review of TransCon PTH and look forward to working with the agency during its review,” said Jan Mikkelsen, President...

Continue reading

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy; LOQTORZI monotherapy also recommended as the only preferred regimen in subsequent lines of therapy – -– LOQTORZI is the first and only FDA-approved treatment for recurrent or metastatic NPC in all lines of therapy– REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) announced today that the National Comprehensive Cancer Network (NCCN) has updated the clinical practice guidelines for nasopharyngeal carcinoma (NPC) to include LOQTORZI™ (toripalimab-tpzi) as a preferred, category 1 first-line treatment option for adults with metastatic or recurrent locally advanced NPC...

Continue reading

RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development

Glen Rock, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), a biopharmaceutical company focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that, on December 6, 2023, it has entered into an agreement with Ponto Ventures LLC providing for Will Clodfelter to serve as RespireRx’s Senior Vice President of Business Development on a part-time basis. Mr. Clodfelter will initially lead the business development efforts with respect to dronabinol, the lead asset of ResolutionRx Ltd, a wholly-owned Australian subsidiary of the Company. Mr. Clodfelter will collaborate with Jeff Eliot Margolis, the Company’s Senior Vice President, Chief Financial Officer,...

Continue reading

HeartCore Implements New Function to Enhance its Market Leading CMS Platform

NEW YORK and TOKYO, Dec. 11, 2023 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or “the Company”), a leading enterprise software and consulting services company based in Tokyo, announced that it has developed and integrated a new “Builder for Creating Admin Screens” functionality into its market leading content management systems (“CMS”) platform, which allows users to create original submission screens within the platform. HeartCore’s latest “Builder for Creating Admin Screens” function allows users of the CMS platform to effortlessly design and customize their own personalized submission screens tailored specifically to individual needs and preferences. Developing a submission screen in many CMS platforms often requires the involvement and expertise of external production entities or proficient webmasters,...

Continue reading

Arbor Realty Trust Announces an Increase of its Share Repurchase Program to $150 Million

UNIONDALE, N.Y., Dec. 11, 2023 (GLOBE NEWSWIRE) — Arbor Realty Trust, Inc. (NYSE: ABR), today announced that its Board of Directors has approved an increase to the Company’s share repurchase program authorizing the Company to repurchase up to $150 million of its outstanding common stock. The share repurchase program allows shares to be repurchased at management’s discretion from time to time in the open market, through privately negotiated transactions or otherwise in compliance with Rule 10b-18 and Rule 10b5-1 under the Securities Exchange Act of 1934. The share repurchase program also permits the Company to establish Rule 10b5-1 trading plans to repurchase its outstanding shares at times when it might otherwise be prevented from doing so. This share repurchase program does not obligate the Company to acquire any particular...

Continue reading

BIGG Digital Assets Co-Founder Shone Anstey Returns as a Strategic Advisor; Update on Digital Asset Due Diligence Audit Service Offering

VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) — BIGG Digital Assets Inc. (“BIGG” or the “Company”) (CSE: BIGG; OTCQX: BBKCF; WKN: A2PS9W), a leading innovator in the digital assets space and owner of Netcoins, and Blockchain Intelligence Group and TerraZero is pleased to announce the addition of Due Diligence Audits to its arsenal of digital asset investigations and compliance services. This strategic move comes in response to the proliferate demand for digital asset auditing solutions arising after the discovery of the multi-billion dollar FTX fraud in November 2022. There is vast business potential, and a regulatory need, within the digital asset market for auditing and due diligence services. BIGG recently completed a proof of reserves and platform due diligence audit for Wonderfi Technologies Inc., Canada’s largest...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.